Evolutionary genomic analysis for ALL

The advantage of genomic monitoring over cytogenetics for clinical assessment of leukemia is illustrated by a case of pediatric acute lymphoblastic leukemia in which a lesion underlying lethal end-stage myeloid disease could be detected by whole-genome sequencing years before the risk manifested cytogenetically.

Automated summary

Genomic monitoring is superior to cytogenetics for clinical assessment of leukemia. A case of pediatric acute lymphoblastic leukemia demonstrates that a lesion underlying lethal end-stage myeloid disease could be detected by whole-genome sequencing years before it manifested cytogenetically.